Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.53 |
| ▸ | GSR | P00390 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29486962 | 1.00 | OTC (0.58) | OTCNOD1GSRGRM8GRM6 | |
| SCHEMBL10005285 | 1.00 | OTC (0.58) | OTCNOD1GSRGRM8GRM6 | |
| SCHEMBL359248 | 0.93 | OTC (0.53) | OTCNOD1GSRGRM8GRM6 | |
| SCHEMBL27776403 | 0.89 | GSR (0.58) | OTCNOD1GSRGRM8GRM6 | |
| SCHEMBL8627837 | 0.89 | OTC (0.51) | OTCNOD1GSRGRM8GRM6 | |
| SCHEMBL1116103 | 0.89 | GSR (0.58) | OTCNOD1GSRGRM8GRM6 | |
| SCHEMBL7996973 | 0.89 | OTC (0.55) | OTCNOD1GSRGRM8GRM6 | |
| SCHEMBL4899060 | 0.89 | OTC (0.51) | OTCNOD1GSRGRM8GRM6 | |
| SCHEMBL18924743 | 0.89 | GSR (0.58) | OTCNOD1GSRGRM8GRM6 | |
| SCHEMBL29590846 | 0.88 | SLC1A1 (0.58) | OTCNOD1GSRGRM8GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961319-B2 | Anti-transglutaminase 2 antibodies | LIFEARC (GB) | 2021-03-30 | — | — | US | claimed |
| EP-3521315-B1 | ANTI-TRANSGLUTAMINASE 2 ANTIBODIES | LIFEARC (GB) | 2020-10-14 | — | — | EP | claimed |
| EP-3521315-A1 | ANTI-TRANSGLUTAMINASE 2 ANTIBODIES | LifeArc (GB) | 2019-08-07 | — | — | EP | claimed |
| EP-2855530-B1 | ANTI-TRANSGLUTAMINASE 2 ANTIBODIES | LIFEARC (GB) | 2019-05-01 | — | — | EP | claimed |
| US-20180355060-A1 | Anti-Transglutaminase 2 Antibodies | LIFEARC (GB) | 2018-12-13 | — | — | US | claimed |
| US-20150218289-A1 | ANTI-TRANSGLUTAMINASE 2 ANTIBODIES | LIFEARC (GB) | 2015-08-06 | — | — | US | claimed |
| WO-2000003739-A9 | (CAG)/Q EXPANSION DISORDERS | CORNELL RES FOUNDATION INC (US) | 2000-11-02 | — | — | WO | claimed |
| US-12559534-B2 | Modified IL-2 proteins, peg conjugates, and uses thereof | CSPC Megalith Biopharmaceutical Co., Ltd. (CN) | 2026-02-24 | — | — | US | disclosed |
| CN-114245802-B | Modified IL-2 proteins, PEG conjugates and uses thereof | 石药集团巨石生物制药有限公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-3155904-B1 | COMPOSITIONS FOR ENHANCING THE QUALITY OF LIFE OF A SENIOR ANIMAL | HILLS PET NUTRITION INC (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-3762049-B1 | METHODS AND KITS FOR PRODUCING A FIBRIN MATRIX | KUROS BIOSURGERY AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| US-11718686-B2 | Anti-transglutaminase 2 antibodies | LIFEARC (GB) | 2023-08-08 | — | — | US | disclosed |
| CN-113817619-B | High-temperature-resistant transglutaminase yzk producing strain and application thereof | 河南省科学院生物研究所有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2005110015-A2 | CROSS-LINKABLE GLYCOPROTEINS AND METHODS OF MAKING THE SAME | OHIO UNIVERSITY (US) | 2005-11-24 | — | — | WO | disclosed |
| US-6852686-B2 | Methods for ameliorating icthyosiform skin diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-02-08 | — | — | US | disclosed |
| WO-2004029096-A2 | POLYSACCHARIDE-BASED POLYMERS AND METHODS OF MAKING THE SAME | UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20030072795-A1 | Methods for ameliorating icthyosiform skin diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2003-04-17 | — | — | US | disclosed |
| WO-2000078937-A1 | METHODS FOR AMELIORATING ICTHYOSIFORM SKIN DISEASES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, ASREPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000003739-A9 | (CAG)/Q EXPANSION DISORDERS | CORNELL RES FOUNDATION INC (US) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000003739-A1 | (CAG)/Q EXPANSION DISORDERS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961319-B2 | Anti-transglutaminase 2 antibodies | TGM2, TGM3, TGM6 | OTC 3447/4885NOD1 4074/4885GSR 1879/4885 |
| US-11718686-B2 | Anti-transglutaminase 2 antibodies | TGM2, TGM3, TGM6 | OTC 3447/4885NOD1 4074/4885GSR 1879/4885 |
| US-12559534-B2 | Modified IL-2 proteins, peg conjugates, and uses thereof | IL2, IL2RA, ILF2 | OTC 3464/4885NOD1 3207/4885GSR 2297/4885 |
| US-20150218289-A1 | ANTI-TRANSGLUTAMINASE 2 ANTIBODIES | TGM2, TGM3, TGM6 | OTC 3447/4885NOD1 4074/4885GSR 1879/4885 |
| US-20180355060-A1 | Anti-Transglutaminase 2 Antibodies | TGM2, TGM3, TGM6 | OTC 3447/4885NOD1 4074/4885GSR 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.